![Michael Cloonan](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Michael Cloonan
Chief Executive Officer at
SIONNA THERAPEUTICS, INC.
Net worth: 24 M $ as of 2026-06-29
Profile
Michael Cloonan is Chief Operating Officer of SAGE Therapeutics, Inc. In the past he held the position of Senior Vice President-US Commercial at Biogen, Inc. Mr. Cloonan received an MBA from the University of Virginia Darden School of Business and an undergraduate degree from College of the Holy Cross (Massachusetts).
Known holdings in public companies
| Company | Date | Number of shares | Valuation | Valuation date |
|---|---|---|---|---|
| 2026-04-20 | 547,343 ( 1.21% ) | 24 M $ | 2026-06-29 |
Michael Cloonan active positions
| Companies | Position | Start |
|---|---|---|
| SIONNA THERAPEUTICS, INC. | Chief Executive Officer | 2021-04-30 |
RA Capital Management LP (Private Equity)
 RA Capital Management LP (Private Equity) Investment ManagersFinance RA Capital invests in both public and private companies located in the United States. The firm targets companies operating in the fields of healthcare and life sciences. It provides financing for pre-seed, seed stage, early stage and growth capital requirements . The firm acts as a lead and co-investor, makes follow-on investments and has a board seat requirement. | Consultant / Advisor | - |
Former positions of Michael Cloonan
| Companies | Position | End |
|---|---|---|
| GENETIX BIOTHERAPEUTICS, INC. | Director/Board Member | 2025-06-01 |
| SAGE THERAPEUTICS, INC. | Chief Operating Officer | 2021-05-02 |
| BIOGEN INC. | Corporate Officer/Principal | 2016-12-31 |
Training of Michael Cloonan
Experiences
Positions held
Active
Inactive
Listed companies
Private companies
Connections
83
1st degree connections
7
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Private companies | 7 |
|---|---|
Biogen, Inc.
 Biogen, Inc. Pharmaceuticals: MajorHealth Technology Manufactures and markets therapies for neurological and neurodegenerative diseases | Health Technology |
College of the Holy Cross (Massachusetts)
 College of the Holy Cross (Massachusetts) Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
bluebird bio, Inc.
 bluebird bio, Inc. BiotechnologyHealth Technology Develops genetic therapies based on blood stem cells | Health Technology |
SAGE Therapeutics, Inc.
 SAGE Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Develops and commercializes novel medicines for central nervous system disorders | Health Technology |
University of Virginia Darden School of Business
 University of Virginia Darden School of Business Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
RA Capital Management LP (Private Equity)
RA Capital Management LP (Private Equity) Investment ManagersFinance RA Capital invests in both public and private companies located in the United States. The firm targets companies operating in the fields of healthcare and life sciences. It provides financing for pre-seed, seed stage, early stage and growth capital requirements . The firm acts as a lead and co-investor, makes follow-on investments and has a board seat requirement. | Finance |
Sionna Therapeutics, Inc.
 Sionna Therapeutics, Inc. BiotechnologyHealth Technology Develops therapies for CF and rare diseases | Health Technology |
- Stock Market
- Insiders
- Michael Cloonan
Choose MarketScreener 
